- Home
- LRE vs PTN Comparison
LRE vs PTN Comparison
Compare LRE & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- PTN
- Stock Information
- Founded
- LRE 2001
- PTN 1986
- Country
- LRE Japan
- PTN United States
- Employees
- LRE N/A
- PTN N/A
- Industry
- LRE
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- PTN Health Care
- Exchange
- LRE Nasdaq
- PTN Nasdaq
- Market Cap
- LRE 29.9M
- PTN 25.4M
- IPO Year
- LRE 2023
- PTN 1993
- Fundamental
- Price
- LRE $1.99
- PTN $1.02
- Analyst Decision
- LRE
- PTN Strong Buy
- Analyst Count
- LRE 0
- PTN 1
- Target Price
- LRE N/A
- PTN $17.00
- AVG Volume (30 Days)
- LRE 37.1K
- PTN 573.0K
- Earning Date
- LRE 01-01-0001
- PTN 02-13-2025
- Dividend Yield
- LRE N/A
- PTN N/A
- EPS Growth
- LRE N/A
- PTN N/A
- EPS
- LRE 0.29
- PTN N/A
- Revenue
- LRE $117,804,154.00
- PTN $2,384,113.00
- Revenue This Year
- LRE N/A
- PTN N/A
- Revenue Next Year
- LRE N/A
- PTN N/A
- P/E Ratio
- LRE $6.79
- PTN N/A
- Revenue Growth
- LRE 8.82
- PTN N/A
- 52 Week Low
- LRE $1.19
- PTN $0.68
- 52 Week High
- LRE $13.76
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- LRE 44.95
- PTN 54.76
- Support Level
- LRE $1.80
- PTN $0.82
- Resistance Level
- LRE $2.15
- PTN $1.20
- Average True Range (ATR)
- LRE 0.19
- PTN 0.12
- MACD
- LRE -0.04
- PTN 0.01
- Stochastic Oscillator
- LRE 25.98
- PTN 64.58
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.